Skip to content

Circulating Serpina3 / EGFR / Adipsin levels in Japanese patients with type 2 diabetes.

Circulating Serpina3 / EGFR / Adipsin levels in Japanese patients with type 2 diabetes. - Circulating Serpina3 / EGFR / Adipsin levels in Japanese patients with type 2 diabetes.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000020474
Enrollment
80
Registered
2016-01-08
Start date
2016-01-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Sponsors

Yokohama City University hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: <Type 2 diabetes group> Hospitalized Patients with type 2 diabetes who fulfilled the following criteria. 1) Age is over 20 and below 70. 2) Patients diagnosed with type 2 diabetes. 3) Having provided voluntary written consent for participation in this study. <Control group> Hospitalized Patients with non-type 2 diabetes who fulfilled the following criteria. 1) Age is over 20 and below 70. 2) Patients who are not diagnosed with type 2 diabetes. 3) Having provided voluntary written consent for participation in this study.

Exclusion criteria

Exclusion criteria: Patients corresponding to any of the following are inapplicable <Type 2 diabetes group> 1)Patients with severe complications( liver disease, mental disorder, cancer) 2)Patients with severe ketosis or diabetic coma. 3)Patients with severe infections, perioperative status, or severe trauma 4) Patients whose baseline eGFR were <29 ml/min/1.73m^2 5)Pregnancy or lactation in women 6) Patients who are judged by an investigator to be inappropriate for this study for any other reason. <Control group> 1)Patients with severe complications( liver disease, mental disorder, cancer) 2)Patients with severe infections, perioperative status, or severe trauma 3)Pregnancy or lactation in women 4) Patients who are judged by an investigator to be inappropriate for this study for any other reason.

Design outcomes

Primary

MeasureTime frame
Serum Serpina3 / EGFR / Adipsin levels

Secondary

MeasureTime frame
The association of the serum Serpina3 / EGFR / Adipsin levels with the various metabolic parameters is analyzed in enrolled subjects.

Countries

Japan

Contacts

Public ContactMayu Kyohara

Yokohama City University Graduate School of Medicine Department of Endocrinology and Metabolism

kyouhara-tym@umin.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026